{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:17:40Z","timestamp":1791497860418,"version":"4.3.4"},"reference-count":72,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medica Sur Clinic and Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alterations in the gut\u2013liver axis and changes in the gut microbiome are among the risk factors for the pathogenesis of non-alcoholic fatty liver disease (NAFLD). These patients show increased bacterial overgrowth in the small intestine and impaired intestinal permeability. Therefore, therapeutic options such as probiotics or prebiotics have been investigated to modulate intestinal microbiota composition to improve NAFLD. Most in vivo and in vitro probiotic studies have focused on reducing hepatic fat accumulation. The beneficial effects of probiotics on NAFLD have been demonstrated in animal models, and the most widely used microorganisms are those of the Lactobacillus and Bifidobacterium genera. In animal models, probiotics help restore the intestinal microbiota and improve the integrity of the intestinal barrier. This narrative review summarizes published evidence and the likely benefits of probiotics and prebiotics as a therapeutic option for patients with NAFLD.<\/jats:p>","DOI":"10.3390\/ijms241914918","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T09:14:22Z","timestamp":1696497262000},"page":"14918","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease"],"prefix":"10.3390","volume":"24","author":[{"given":"Alejandra","family":"Mijangos-Trejo","sequence":"first","affiliation":[{"name":"M\u00e9dica Sur, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Nu\u00f1o-Lambarri","sequence":"additional","affiliation":[{"name":"M\u00e9dica Sur, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varenka","family":"Barbero-Becerra","sequence":"additional","affiliation":[{"name":"M\u00e9dica Sur, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misael","family":"Uribe-Esquivel","sequence":"additional","affiliation":[{"name":"M\u00e9dica Sur, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Vidal-Cevallos","sequence":"additional","affiliation":[{"name":"M\u00e9dica Sur, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7451-3306","authenticated-orcid":false,"given":"Norberto","family":"Ch\u00e1vez-Tapia","sequence":"additional","affiliation":[{"name":"M\u00e9dica Sur, Mexico City 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: A consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.arcmed.2020.11.010","article-title":"Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease","volume":"52","author":"Makri","year":"2021","journal-title":"Arch. Med. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"997018","DOI":"10.3389\/fcimb.2022.997018","article-title":"Gut dysbiosis in nonalcoholic fatty liver disease: Pathogenesis, diagnosis, and therapeutic implications","volume":"12","author":"Fang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s10482-020-01474-7","article-title":"Human gut microbiota\/microbiome in health and diseases: A review","volume":"113","author":"Gomaa","year":"2020","journal-title":"Antonie Van Leeuwenhoek"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Milosevic, I., Vujovic, A., Barac, A., Djelic, M., Korac, M., Radovanovic Spurnic, A., Gmizic, I., Stevanovic, O., Djordjevic, V., and Lekic, N. (2019). Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020395"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: Pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Di Tommaso, N., Gasbarrini, A., and Ponziani, F.R. (2021). Intestinal Barrier in Human Health and Disease. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph182312836"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.gastro.2020.04.077","article-title":"Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders","volume":"159","author":"Chopyk","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1136\/gutjnl-2020-322260","article-title":"Mucus barrier, mucins and gut microbiota: The expected slimy partners?","volume":"69","author":"Paone","year":"2020","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.molmed.2021.06.007","article-title":"The gut vascular barrier: A new player in the gut\u2013liver\u2013brain axis","volume":"27","author":"Brescia","year":"2021","journal-title":"Trends Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00535-019-01649-8","article-title":"Intestinal microbiome and NAFLD: Molecular insights and therapeutic perspectives","volume":"55","author":"Hu","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41423-020-00592-6","article-title":"Gut microbiome, liver immunology, and liver diseases","volume":"18","author":"Wang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/jgh.15512","article-title":"Gut-liver-axis: Barrier function of liver sinusoidal endothelial cell","volume":"36","author":"Wang","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","article-title":"The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)","volume":"76","author":"Safari","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.chom.2020.07.007","article-title":"Microbiota and Fatty Liver Disease\u2014The Known, the Unknown, and the Future","volume":"28","author":"Lang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1053\/j.gastro.2020.01.049","article-title":"Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?","volume":"158","author":"Warmbrunn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vallianou, N., Christodoulatos, G.S., Karampela, I., Tsilingiris, D., Magkos, F., Stratigou, T., Kounatidis, D., and Dalamaga, M. (2021). Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules, 12.","DOI":"10.3390\/biom12010056"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Castillo, V., Figueroa, F., Gonz\u00e1lez-Pizarro, K., Jopia, P., and Ibacache-Quiroga, C. (2021). Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. Foods, 10.","DOI":"10.3390\/foods10081719"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Chlebicz-W\u00f3jcik, A., and \u015ali\u017cewska, K. (2021). Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review. Biomolecules, 11.","DOI":"10.3390\/biom11081154"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Moszak, M., Szuli\u0144ska, M., Walczak-Ga\u0142\u0119zewska, M., and Bogda\u0144ski, P. (2021). Nutritional Approach Targeting Gut Microbiota in NAFLD\u2014To Date. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18041616"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ji, Y., Yin, Y., Sun, L., and Zhang, W. (2020). The Molecular and Mechanistic Insights Based on Gut\u2013Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093066"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"113138","DOI":"10.1016\/j.biopha.2022.113138","article-title":"Postbiotics as potential new therapeutic agents for metabolic disorders management","volume":"153","author":"Bourebaba","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lv, H., Tao, F., Peng, L., Chen, S., Ren, Z., Chen, J., Yu, B., Wei, H., and Wan, C. (2023). In Vitro Probiotic Properties of Bifidobacterium animalis subsp. lactis SF and Its Alleviating Effect on Non-Alcoholic Fatty Liver Disease. Nutrients, 15.","DOI":"10.3390\/nu15061355"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhu, L., Liao, R., Huang, J., Xiao, C., Yang, Y., Wang, H., He, D., Yan, H., and Yang, C. (2022). Lactobacillus salivarius SNK-6 Regulates Liver Lipid Metabolism Partly via the miR-130a-5p\/MBOAT2 Pathway in a NAFLD Model of Laying Hens. Cells, 11.","DOI":"10.3390\/cells11244133"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijfoodmicro.2011.11.020","article-title":"In vitro testing of commercial and potential probiotic lactic acid bacteria","volume":"153","author":"Jensen","year":"2012","journal-title":"Int. J. Food Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Endo, H., Niioka, M., Kobayashi, N., Tanaka, M., and Watanabe, T. (2013). Butyrate-Producing Probiotics Reduce Nonalcoholic Fatty Liver Disease Progression in Rats: New Insight into the Probiotics for the Gut-Liver Axis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063388"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1930874","DOI":"10.1080\/19490976.2021.1930874","article-title":"Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice","volume":"13","author":"Hong","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.29219\/fnr.v64.3751","article-title":"Bile salt hydrolase-overexpressing Lactobacillus strains can improve hepatic lipid accumulation in vitro in an NAFLD cell model","volume":"64","author":"Huang","year":"2020","journal-title":"Food Nutr. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0352-x","article-title":"A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption","volume":"51","author":"Jang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Nguyen, H.T., Gu, M., Werlinger, P., Cho, J.H., Cheng, J., and Suh, J.W. (2022). Lactobacillus sakei MJM60958 as a Potential Probiotic Alleviated Non-Alcoholic Fatty Liver Disease in Mice Fed a High-Fat Diet by Modulating Lipid Metabolism, Inflammation, and Gut Microbiota. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113436"},{"key":"ref_32","first-page":"380316","article-title":"Cholesterol Assimilation by Lactobacillus Probiotic Bacteria: An In Vitro Investigation","volume":"2014","author":"Jones","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AEM.69.8.4743-4752.2003","article-title":"An In Vitro Study of the Probiotic Potential of a Bile-Salt-Hydrolyzing Lactobacillus fermentum Strain, and Determination of Its Cholesterol-Lowering Properties","volume":"69","author":"Pereira","year":"2003","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_34","first-page":"350","article-title":"Lactobacillus plantarum DR7 Reduces Cholesterol via Phosphorylation of AMPK That Down-regulated the mRNA Expression of HMG-CoA Reductase","volume":"38","author":"Lew","year":"2018","journal-title":"Korean J. Food Sci. Anim. Resour."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8273","DOI":"10.1007\/s00253-013-5088-2","article-title":"Cholesterol-lowering probiotics: In vitro selection and in vivo testing of bifidobacteria","volume":"97","author":"Bordoni","year":"2013","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.molmet.2019.08.020","article-title":"Fibroblast growth factor 21 is required for the therapeutic effects of Lactobacillus rhamnosus GG against fructose-induced fatty liver in mice","volume":"29","author":"Zhao","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e00183-20","DOI":"10.1128\/mSphere.00183-20","article-title":"Secretion of Recombinant Interleukin-22 by Engineered Lactobacillus reuteri Reduces Fatty Liver Disease in a Mouse Model of Diet-Induced Obesity","volume":"5","author":"Oh","year":"2020","journal-title":"mSphere"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2264737","DOI":"10.1155\/2021\/2264737","article-title":"Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota\/FXR\/FGF15 Signaling Pathway","volume":"2021","author":"Luo","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1071284","DOI":"10.3389\/fnut.2022.1071284","article-title":"Lactobacillus plantarum ZJUIDS14 alleviates non-alcoholic fatty liver disease in mice in association with modulation in the gut microbiota","volume":"9","author":"Cao","year":"2023","journal-title":"Front. Nutr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1177\/0960327121999445","article-title":"Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT\/mTOR\/LC-3II pathways","volume":"40","author":"Salem","year":"2021","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1039\/D0FO01823F","article-title":"Lactobacillus fermentum CQPC06 in naturally fermented pickles prevents non-alcoholic fatty liver disease by stabilizing the gut\u2013liver axis in mice","volume":"11","author":"Mu","year":"2020","journal-title":"Food Funct."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1007\/s00253-020-10633-9","article-title":"Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation","volume":"104","author":"Zhao","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/j.gastro.2020.03.010","article-title":"Lactococcus lactis Subspecies cremoris Elicits Protection against Metabolic Changes Induced by a Western-Style Diet","volume":"159","author":"Naudin","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jnutbio.2010.10.002","article-title":"Probiotics as an emerging therapeutic strategy to treat NAFLD: Focus on molecular and biochemical mechanisms","volume":"22","author":"Iacono","year":"2011","journal-title":"J. Nutr. Biochem."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kobyliak, N., Falalyeyeva, T., Virchenko, O., Mykhalchyshyn, G., Bodnar, P., Spivak, M., Yankovsky, D., Beregova, T., and Ostapchenko, L. (2016). Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention. BMC Gastroenterol., 16.","DOI":"10.1186\/s12876-016-0451-2"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"45176","DOI":"10.1038\/srep45176","article-title":"Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia","volume":"7","author":"Xue","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"487659","DOI":"10.1155\/2020\/5487659","article-title":"Protective Role of Probiotic Supplements in Hepatic Steatosis: A Rat Model Study","volume":"2020","author":"Azarang","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1002\/ctm2.634","article-title":"Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease","volume":"11","author":"Yu","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"336","DOI":"10.4093\/dmj.2019.0042","article-title":"Combination of Probiotics and Salvia miltiorrhiza Polysaccharide Alleviates Hepatic Steatosis via Gut Microbiota Modulation and Insulin Resistance Improvement in High Fat-Induced NAFLD Mice","volume":"44","author":"Wang","year":"2020","journal-title":"Diabetes Metab. J."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Liu, Z.S., Li, P.L., Ku, Y.W., and Chen, P.W. (2022). Oral Administration of Recombinant Lactoferrin-Expressing Probiotics Ameliorates Diet-Induced Lipid Accumulation and Inflammation in Non-Alcoholic Fatty Liver Disease in Mice. Microorganisms, 10.","DOI":"10.3390\/microorganisms10112215"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1039\/C9FO02905B","article-title":"Bifidobacterium adolescentis and Lactobacillus rhamnosus alleviate non-alcoholic fatty liver disease induced by a high-fat, high-cholesterol diet through modulation of different gut microbiota-dependent pathways","volume":"11","author":"Wang","year":"2020","journal-title":"Food Funct."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Hu, W., Cassard, A.M., and Ciocan, D. (2022). Pectin in Metabolic Liver Disease. Nutrients, 15.","DOI":"10.3390\/nu15010157"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1136\/gutjnl-2020-321565","article-title":"Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury","volume":"70","author":"Wrzosek","year":"2021","journal-title":"Gut"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ciocan, D., Spatz, M., Trainel, N., Hardonni\u00e8re, K., Domenichini, S., Mercier-Nom\u00e9, F., Desmons, A., Humbert, L., Durand, S., and Kroemer, G. (2022). Modulation of the Bile Acid Enterohepatic Cycle by Intestinal Microbiota Alleviates Alcohol Liver Disease. Cells, 11.","DOI":"10.3390\/cells11060968"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1007\/s00253-022-11946-7","article-title":"Identification of a protective Bacteroides strain of alcoholic liver disease and its synergistic effect with pectin","volume":"106","author":"Wang","year":"2022","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Qian, M., Lyu, Q., Liu, Y., Hu, H., Wang, S., Pan, C., Duan, X., Gao, Y., Qi, L.W., and Liu, W. (2019). Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice. Mar. Drug, 17.","DOI":"10.3390\/md17070391"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jconrel.2022.06.031","article-title":"Prebiotic-like cyclodextrin assisted silybin on NAFLD through restoring liver and gut homeostasis","volume":"348","author":"Ren","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"J. Food Sci."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Mohamad Nor, M.H., Ayob, N., Mokhtar, N.M., Raja Ali, R.A., Tan, G.C., Wong, Z., Shafiee, N.H., Wong, Y.P., Mustangin, M., and Nawawi, K.N.M. (2021). The Effect of Probiotics (MCP\u00ae BCMC\u00ae Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients, 13.","DOI":"10.3390\/nu13093192"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Chong, P.L., Laight, D., Aspinall, R.J., Higginson, A., and Cummings, M.H. (2021). A randomised placebo controlled trial of VSL#3\u00ae probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01660-5"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Duseja, A., Acharya, S.K., Mehta, M., Chhabra, S., Rana, S., Das, A., Dattagupta, S., Dhiman, R.K., and Chawla, Y.K. (2019). High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): A randomised, double-blind, proof of concept study. BMJ Open Gastroenterol., 6.","DOI":"10.1136\/bmjgast-2019-000315"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","article-title":"Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease","volume":"9","author":"Ahn","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur. J. Nutr."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chong, C.Y.L., Orr, D., Plank, L.D., Vatanen, T., O\u2019Sullivan, J.M., and Murphy, R. (2020). Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients, 12.","DOI":"10.3390\/nu12040937"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ajcn\/nqz042","article-title":"Gut microbiome\u2013targeted therapies in nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression","volume":"110","author":"Sharpton","year":"2019","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1080\/17474124.2022.2016391","article-title":"Effects of probiotics on nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"15","author":"Yang","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/MEG.0000000000001371","article-title":"The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease\u2014A systematic review and meta-analysis","volume":"31","author":"Khan","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"862266","DOI":"10.3389\/fpubh.2022.862266","article-title":"The promising role of probiotics\/prebiotics\/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis","volume":"10","author":"Li","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_69","first-page":"7888076","article-title":"Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease","volume":"2022","author":"Huang","year":"2022","journal-title":"Comput. Math. Methods Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e32734","DOI":"10.1097\/MD.0000000000032734","article-title":"Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis","volume":"102","author":"Zhou","year":"2023","journal-title":"Medicine"},{"key":"ref_71","first-page":"CD013157","article-title":"Nutritional supplementation for nonalcohol-related fatty liver disease: A network meta-analysis","volume":"7","author":"Komolafe","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Maurizi, V., Rinninella, E., Tack, J., Di Berardino, A., Santori, P., Rasetti, C., Procopio, A.C., Boccuto, L., and Scarpellini, E. (2022). Fecal Microbiota Transplantation in NAFLD Treatment. Medicina, 58.","DOI":"10.3390\/medicina58111559"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/19\/14918\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:01:33Z","timestamp":1760130093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/19\/14918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":72,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["ijms241914918"],"URL":"https:\/\/doi.org\/10.3390\/ijms241914918","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]}}}